CPD-1061

CPD-1061 is a biological investigational agent developed by the Centre for Probe Development & Commercialization (CPDC). It is used as a pre-targeting dose in combination with radiolabeled agents for imaging or therapeutic purposes in oncology, specifically in patients with solid tumors. In clinical studies, CPD-1061 has been administered prior to [I-124]-CPD-1028 injection to enhance tumor targeting and biodistribution of the radiopharmaceutical. The primary indication under investigation is neoplasms (solid tumors), and its mechanism involves pre-targeting strategies that may improve the delivery of diagnostic or therapeutic radionuclides to tumor cells[1][3][4]. The specific molecular target or detailed mechanism of action for CPD-1061 has not been disclosed publicly.